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Abstract Bisphosphonates (BPs) are well established as
an important class of drugs for the treatment and preven-
tion of several bone disorders including osteoporosis. This
work investigated the interaction of two bisphosphonates,
risedronate and tiludronate, with several apatitic supports, a
well-crystallised hydroxyapatite (HA) and nanocrystalline
apatites with varying maturation times, chemical compo-
sition and surface characteristics. The purpose was to fully
understand the adsorption mechanism and desorption pro-
cess, by the evaluation of the effect of several physico-
chemical parameters (temperature, pH and concentration of
calcium and phosphate ions). Whatever the nature of the
BP and the structure and composition of the apatite, the
adsorption of such anti-resorptive agents can be well
described as an ion exchange-reaction between phosphates
species on the apatitic surface and BP molecules in
solution. However, the parameters of adsorption can vary
depending on the physicochemical conditions of the
adsorption reaction. In addition, the structure and compo-
sition of the apatitic surface also influence the adsorption
properties. Finally, BPs molecules are slowly released from
apatitic supports, because most of the adsorbed molecules
are irreversibly bound and not spontaneously released by
dilution or simple washing. Moreover, similar to their
adsorption, the release of bisphosphonates is strongly
affected not only by the chemical properties of the mole-
cule, but also by the chemical and structural characteristics
of the apatitic substrates. The understanding of the
adsorption and release processes provides fundamental
tools for the development of drug delivery systems using
apatite materials.
1 Introduction
Bisphosphonates (BPs) are well established as an important
class of drugs for the treatment and prevention of several
bone disorders including osteoporosis. BPs are stable
synthetic analogues of inorganic pyrophosphate character-
ised by a non-hydrolysable P-C-P structure with two
phosphonate groups attached to the same carbon [1, 2].
Their mode of action comes from both physicochemical
effects and biological activity: like pyrophosphate, BPs
present a high affinity to adsorb onto bone mineral, and
thereby prevent mineral dissolution and bone resorption,
inhibiting osteoclasts activity. BPs have two additional
substituents in their molecule attached to the central car-
bon, which may significantly affect both the mineral
adsorption affinity and the cell activity : the ability of BPs
to bind to bone mineral is increased by a functional group
able to co-ordinate to calcium such as a hydroxyl group
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(OH) [1, 2], and those containing a nitrogen atom within a
heterocyclic ring (such as risedronate and zoledronate)
have the most potent antiresorptive effect [3].
The classic BPs treatment is the systemic way by oral
administration or intravenous injection. However, systemic
use of BPs can result in undesirable side-effects like fever
[4], ulcers [5, 6] or osteonecrosis of the jaw especially with
intravenous injection [7]. Moreover, low bioavailability is
commonly associated with oral administration [8]. In order
to avoid these adverse effects and increase BPs bioavail-
ability, the development of strategies for local adminis-
tration of such antiosteoporotic drugs at bone sites
exhibiting a risk of facture becomes even more interesting.
Taking into account the affinity of BPs for bone, calcium
phosphate-based biomaterials appear to be appropriate
carriers for such molecules. Few studies have focused on
the development of bioactive implants based on calcium
phosphates for BPs local release, such as ceramics [9, 10]
or cements [11]. An interesting approach is based on the
adsorption of such drugs on apatitic supports such as
stoichiometric hydroxyapatite (HA, Ca10(PO4)6(OH)2)
[12]. Previous studies show that the presence of BPs spe-
cies in solution participates in an ionic exchange process
with active mineral ions on the apatite surface in which the
apatitic crystals/BP association can be chemically con-
trolled [13]. However, very few studies have investigated
the release of BPs from nanocrystalline apatites (NCA)
[14]. Compared to well crystallised hydroxyapatite (HA),
NCA samples present a structured hydrated layer at the
surface, which is responsible for a high superficial ionic
mobility and represents an ‘‘important ion reser-
voir’’ allowing ionic exchange with the solution. This
layer is related to the precipitation process at physiological
pH and its structure as well its extension depend on the
ageing time: the hydrated layer disappears when the ageing
time (also referred to as maturation time) increases [15].
On the basis of these previous observations, this work
investigated the interaction of two bisphosphonates,
risedronate and tiludronate (Fig. 1), with several apatitic
supports, a well-crystallised hydroxyapatite (HA) and
biomimetic nanocrystalline apatites (NCA) with varying
maturation times, leading to hydrated surface layers with
different thicknesses and variable chemical compositions
and Ca/(P?C) ratio, related to calcium deficiency as
explained in earlier studies [16]. The purpose was to fully
understand the adsorption mechanism and desorption pro-
cess, by the evaluation of the effect of several physico-
chemical parameters (temperature, pH and concentration of
calcium and phosphate ions). The data presented were
obtained at different periods with BP samples obtained
from different pharmaceutical laboratories, and some
experiments are specific to one kind of BP due to the
limited amount of drug we could obtain. Therefore, the
release kinetics were performed on tiludronate only. The
understanding of the adsorption and release processes
provides fundamental tools for the development of drug
delivery systems using apatite materials.
2 Materials and methods
2.1 Materials
Well crystallised hydroxyapatite (HA) was synthesised by
double decomposition between a phosphate salt solution
(NH4)2HPO4 (433.3 mL, 1.54 M in deionised water) and a
calcium salt solution Ca(NO3)2.4H2O (1,100 mL, 1 M in
deionised water). The phosphate solution was added
dropwise for about 3 h into the calcium solution main-
tained at 90 C under continuous stirring [17]. The pH of
the suspension was around 10. After filtration, the precip-
itate was washed and lyophilised. Then the powder was
sieved (\125 lm) and stored in a freezer.
Nanocrystalline apatites (NCA) were synthesised by a
double decomposition process at physiological pH, by
pouring rapidly at ambient temperature a cationic solution
containing calcium nitrate salt (Ca(NO3)2.4H2O,
C = 0.29 M, 750 mL) into an anionic solution containing
ammonium phosphate salt with an excess of phosphate ions
for buffering the solution and sodium bicarbonate salt
((NH4)2HPO4, C = 0.60 M, NaHCO3, C from 0 to 0.71 M,
1,500 mL) [18]. The suspension was left to mature at room
temperature without stirring. Several NCAs were synthes-
ised by varying the maturation times (from 0 to 30 days)
and carbonate content during the synthesis. The precipi-
tates obtained were quickly vacuum filtered, washed with
deionised water and freeze-dried. The powders were then
sieved (\125 lm) and stored in a freezer.
The calcium content of the synthesised solids was
determined by complexometry with EDTA and the
Fig. 1 Chemical structure of a tiludronate disodium salt and
b risedronate monosodium salt
phosphate content was obtained by UV spectrophotometry
of phosphovanado molybdic acid complex [19]. The rela-
tive error on the level of calcium and phosphate was 0.5 %.
The determination of the atomic Ca/P ratio of the precip-
itate had a relative error of 1 %. The level of carbonate ions
was measured by a coulometry technique (UIC, Inc. CM
5014 coulometer with CM 5130 acidification unit). The
specific surface area of the crystals was measured by
nitrogen adsorption according to the BET method using a
quantachrome instruments monosorb NOVA 1000. Pow-
dered tiludronate (di-sodium((4-chlorophenyl)thio)methylene-
bis-phosphonate) hemihydrate and risedronate (monosodium
(1-hydroxy-2-(3-pyridinyl)ethylidene-bis-phosphonate) hemi-
pentahydrate samples were a gift from Sanofi Aventis and
Procter & Gamble, respectively (Fig. 1).
2.2 Adsorption experiments
The apatite sample (50 mg of HA or NCA) was dispersed
in 5 mL of the adsorption medium, an aqueous solution of
bisphosphonate (risedronate or tiludronate in 1 mM
potassium chloride aqueous solution), in a polyethylene
tube by sonication for few minutes. The suspensions
obtained were incubated for 2 h without stirring and
centrifuged for 20 min at 5,000 rpm. The supernatants
were obtained by filtration through Millipore filters (pore
size 0.2 lm) and analysed. Blanks containing only the
adsorption solution incubated without solid were used as
controls.
The adsorption experiments were performed in 1 mM
potassium chloride aqueous solution. The tests were also
carried out under different conditions to determine the effect
of temperature (physiological temperature (37 ± 1 C) and/
or room temperature (25 ± 1 C)), pH (by addition of HCl
or KOH solution in the adsorption solution) and solution
composition (by addition of calcium chloride (0–0.2 mM) or
potassium phosphate (0–10 mM)).
2.3 Adsorption reversibility assays
Adsorption reactions, such as those involved in obtaining
Langmuir adsorption isotherms, are supposed to be
reversible, and changes in the equilibrium concentrations in
solution (far enough from concentrations corresponding to
the surface saturation (or plateau) of the isotherms) result
in changes in adsorbed amounts. Desorption was examined
at 25 and 37 C with respect to dilution, and adsorption
experiments were performed as described above using HA
sample and risedronate (50 mg of solid dispersed in 1 mM
potassium chloride solution containing risedronate). The
suspensions obtained after adsorption were centrifuged,
and portions of the supernatants were removed and
replaced by the same volume of a solution (1 mM
potassium chloride solution without risedronate) previously
equilibrated with HA powder, in order to prevent any
dissolution of the substrate. The sediments were re-dis-
persed and incubated for 2 h to reach new adsorption
equilibrium; the suspensions obtained were again centri-
fuged and the risedronate concentration determined in the
supernatant solution.
The specific role of phosphate ions in the reversibility
was also evaluated by a similar method using for dilution
the same volume of 1 mM potassium chloride aqueous
solution containing various amounts of phosphate salt (2.5,
12.5 and 25 mM of potassium phosphate).
2.4 Solution analysis
The risedronate and tiludronate concentrations in solution
were determined using UV adsorption spectrophotometry
at 262 and 265 nm, respectively (Hewlett Packard 8452A
Diode Array Spectrophotometer). Phosphate concentration
was determined by UV spectrophotometry of phosphova-
nado molybdic acid complex [19] and calcium content by
Inductively Coupled Plasma Atomic Emission Spectros-
copy (ICP-AES, Horiba Jobin Horibo).
2.5 Release kinetics
Tiludronate release profiles were obtained with a flow-
through cells system (USP Apparatus 4 Sotax CE6, Sotax
AG, Switzerland) with 12 mm cells (6 mL) and a piston
pump (Sotax CY7, Sotax AG, Switzerland). In all experi-
ments, laminar flow was used with a bed of 1 g of glass
beads covered with 100 mg of NCA sample after tiludro-
nate adsorption. The release tests were carried out at
37.0 ± 0.5 C under sink conditions according to Euro-
pean Pharmacopoeia guidelines [20]. The dissolution
medium used was deionised water pumped through the
column at a flow rate of 15 mL/min. A closed system was
used, recycling 50 mL of dissolution medium. Periodically,
fractions of 5 mL were collected and tiludronate content
was determined by UV spectroscopy at 265 nm (Hewlett
Packard 8452A Diode Array Spectrophotometer). The
same volume of dissolution medium was replaced back
after each sampling in order to maintain constant volume
and sink conditions. Each release study was performed in
triplicate. The results are presented as kinetics cumulative
of BP released (%) as a function of time:
BP releasedð%Þ ¼ 100  Qr cumul
Qads
ð1Þ
where Qr cumul is the cumulative concentration of BP
released (mmol/L) and Qads the initial quantity of tiludro-
nate adsorbed (mmol/L).
3 Results
3.1 Adsorption experiments
The results of chemical analysis and specific surface area
of the adsorbents used in this study are shown in Table 1.
The evolution of the amount of risedronate and tiludr-
onate adsorbed Qads (lmol/m
2) from the diluted solutions
on several apatitic samples as a function of their remaining
concentration in solution Ceq (mmol/L) is plotted in Fig. 2.
The isotherms obtained are Langmuirian in shape, what-
ever the nature of the BPs and the apatitic support, as
previously published [3, 12]. The adsorption plateaus were
reached at relatively low bisphosphonate concentrations,
indicating a high affinity of these molecules for apatitic
surface. The parameters of the isotherms can be deduced
from the Langmuir equation:
Q ¼ KNCe
1þ ðKCeÞ ð2Þ
by plotting Ce/Q versus Ce, where Ce (mmol/L) and Q
(lmol/m2) correspond to the stationary concentration in the
solution and the amount adsorbed per unit area, respec-
tively. The linear regression provides a way to determine
the adsorption parameters: N is the maximum amount
adsorbed of BP (lmol/m2) and K the affinity constant of
BP for the apatitic surface (L/mmol). As we can see in
Fig. 2, the amount adsorbed at saturation on the HA
specimen appears higher for risedronate than tiludronate
and thus, the chemical structure of bisphosphonates influ-
ences their capacity of adsorption. Moreover, Fig. 2 illus-
trates the fact that the quantity of risedronate adsorbed at
saturation on a well crystallised apatite (HA) appears
always lower than that found for a nanocrystallised apatite
(NCA). Figure 3 reports the variation of the adsorption
parameters on several types of NCA crystals for tiludronate
and risedronate. The data obtained evidence the influence
of the nature of the apatitic surface on the values of the
adsorption parameters: a decrease in the maximum amount
adsorbed at saturation, N, with the maturation time and the
development of the surface hydrated layer. For long
maturation times, in the case of tiludronate, a strong dif-
ference in the values of affinity constant, K, is observed,
related possibly to changes in chemical composition.
The effect of the solution composition on the adsorption
was investigated in detail. The results obtained for risedr-
onate adsorbed on HA for various solution compositions
are presented in Table 2. Although the adsorption experi-
ments were conducted under different conditions, the
curves obtained always corresponded to Langmuir iso-
therms (data not shown). The uptake of risedronate by HA
was dependent on the content of hydroxonium, phosphate
and calcium ions in the solution. The variation of pH in the
standard solutions at room temperature (Table 2a) showed
that the apparent affinity constant (K) and the maximum
amount adsorbed (N) decreased as the pH rose. As it can be
seen, the amount loaded at pH 6.6 is about three times
higher than the value obtained at pH 9.5. Furthermore, the
influence of adding phosphate into the adsorption solution
was examined (Table 2b). Increasing the phosphate con-
centration resulted in a decrease of the maximum amount
adsorbed and the apparent affinity constant. By contrast, as
the calcium concentration rose from 0.05 to 0.2 mM
Table 1 Main characteristics of the adsorbents used in this study
Adsorbent CO3 (wt%)
(±1 %)
Ca/P (±1 %) Ca/(P?C)
(±2 %)
Specific surface area
(m2/g) (±5 %)
HA – 1.64 ± 0.02 1.64 ± 0.03 59 ± 3
NCA maturated for 1 day with carbonate 3.5 ± 0.1 1.53 ± 0.02 1.38 ± 0.03 96 ± 5
NCA maturated for 7 days with carbonate 4.5 ± 0.1 1.59 ± 0.02 1.39 ± 0.03 201 ± 10
NCA maturated for 1 month with carbonate 5.5 ± 0.1 1.62 ± 0.02 1.38 ± 0.03 190 ± 9
NCA maturated for 1 month without carbonate 0.5 ± 0.1 1.61 ± 0.02 1.59 ± 0.03 154 ± 8
NCA non maturated without carbonate 0.3 ± 0.1 1.40 ± 0.02 1.39 ± 0.03 193 ± 9
Fig. 2 Adsorption isotherms of tiludronate (Tilu) and risedronate
(Rise) at 37 C and pH 7.4 on HA and NCA (carbonated and
maturated for one day with Ca/(P?C) = 1.38 ± 0.03). The data
depend on the nature of the apatitic adsorbent surface and of the
adsorbate molecule
(Table 2c), a slight increase in the apparent affinity
occurred, whereas no significant change was noted for the
maximum amount of adsorbed risedronate. The range of
calcium concentration investigated was lower than that of
phosphate ions to prevent the formation of Ca–risedronate
precipitate. These findings suggested that the content of
mineral ions in the solution played an important role in the
uptake of risedronate by apatite crystals, and that these
species should be considered, to some extent, in the eval-
uation of the driving factors in the adsorption process.
3.2 Influence of adsorption on the solution composition
As previously published [13, 21], the analyses of the
solutions after adsorption revealed that the binding of
bisphosphonates molecules to the apatite surface affects the
amount of ionic species in the solution. Figure 4 presents
the variation of calcium and phosphate ion concentrations
in the solution as a function of tiludronate adsorbed on
NCA sample (non carbonated and maturated for 1 month,
with Ca/P = 1.61 ± 0.02). The amount of calcium content
in the solution remained very low (\10 ppm considering a
NCA sample, lower for HA), whereas the release of
phosphate ions increased linearly with the amount of
adsorbed tiludronate, with a slope close to 2.35 ± 0.16.
The uptake of tiludronate is proportional to the amount of
phosphate ions released in the solution indicating that the
main reaction is an ion-exchange process involving surface
anions, whatever the apatitic surface, as previously
Fig. 3 a Adsorption parameters of risedronate for different matura-
tion times of NCA. The Ca/(P?C) ratio remains constant in the solids
and equal to 1.38 (±2 %) indicating a similar amount of bivalent
anions and calcium vacancies. The carbonate content varies from 3.5
wt% ± 1 % for one day to 5.5 wt% ± 1 % for 30 days of maturation
state related to a progressive replacement of HPO4
2- ions by
carbonate ions during maturation. Most importantly the surface
hydrated layer considerably decreased with the maturation time. The
data indicate a decrease of the maximum amount adsorbed at
saturation N with the maturation time. b Adsorption parameters of
tiludronate on two NCA maturated for one month with and without
carbonate. The surface hydrated layer appears more important for the
most carbonated sample. The data indicate a variation of N and K
possibly related to the development of the surface hydrated layer and
its composition[13, 16]
Table 2 Influence of the solution composition on the adsorption
parameters of risedronate by HA, i.e. maximum amount adsorbed
(N) and apparent affinity constant (K): (a) influence of pH at 25 C,
(b) influence of phosphate concentration at pH 7.4 and 37 C,
(c) influence of calcium concentration at pH 7.4 and 37 C
N ± DN (lmol/m2) K ± DK L/mmol)
(a) pH (25 C) (±0.05)
6.60 2.3 ± 0.1 53.3 ± 15.7
7.50 1.6 ± 0.1 7.6 ± 1.2
9.50 0.8 ± 0.1 4.9 ± 1.0
(b) Phosphate added (37 C) (mM)
1.00 2.2 ± 0.1 12.4 ± 4.2
5.00 1.9 ± 0.0 11.8 ± 2.2
10.00 1.9 ± 0.0 9.7 ± 2.2
(c) Calcium added (37 C) (mM)
0.05 2.1 ± 0.1 18.9 ± 6.8
0.20 2.1 ± 0.0 22.7 ± 10.3
Fig. 4 Concentration of phosphate (Open square) and calcium (Open
circle) ions released (mM) in solution as a function of the amount of
tiludronate adsorbed on the solid (Q in mM). The adsorption was
performed on NCA sample non-carbonated and maturated for
1 month (Ca/P = 1.61 ± 0.02 = X). The slope of the straight line
was equal to 2.35 ± 0.16. The dashed lines correspond to the
variation of phosphates species in solution if the uptake of BP were
related to the dissolution of the apatite and the precipitation of Ca2BP
(slope equal to 2/X) or CaBP (slope equal to 1/X) salts
published [13, 22, 23]. However, the slope of the straight
line is different depending on the calcium phosphate
sample and the bisphosphonate used: a slope close to 1 for
the adsorption of risedronate on HA and NCA [21], and
from 1.2 to 2.3 for tiludronate on several nanocrystalline
apatites [13]. Therefore, the number of phosphate groups
released per single adsorbed molecule of tiludronate (cor-
responding to the slope) varies depending on the nature of
the support and the chemical structure of the BPs.
3.3 Adsorption reversibility assays
Figure 5 presents the adsorption isotherms and the results
of reversibly assays of risedronate adsorption performed at
25 and 37 C. A simple comparison over the range of
concentrations investigated indicated that the highest
adsorption capacity was observed at 37 C (Fig. 5, solid
symbols). Thus, the amount of risedronate adsorbed
reached 2.50 lmol/m2 at 37 C vs. 1.56 lmol/m2 at 25 C.
The reversibility assays involve a decrease of the risedro-
nate concentration in the solution by diluting with a KCl
solution 1 mM (Fig. 5, open symbols). The dashed lines
indicate that the decrease in the equilibrium concentration
of given points from the isotherms did not change the
values of the corresponding amounts adsorbed. This
observation suggests that the adsorption process is irre-
versible with respect to dilution in the range of concen-
trations examined. A similar trend was noted for the two
temperatures investigated (25 and 37 C).
However, the desorption data present different results in
the presence of phosphate ions (0–25 mM) in the solution
(Fig. 6). The increase of phosphate species in solution
involves the release of BPs molecules from the apatite
surface by ion-exchange.
3.4 Release kinetics
The results of the kinetics of release of tiludronate (%)
from several NCAs with a Ca/(P?C) ratio constant (equal
to 1.38 ± 0.03) are presented in Fig. 7. In all samples, the
release was fast during the first hour and slowed down
afterwards. The total amount released was significantly
lower for matured (1 month) NCA than the non-maturated
NCA. However, the quantities of BPs released represented
a minor fraction of the total amount adsorbed for all the
samples: around 5–6 % of the initial quantity adsorbed for
the non-matured NCA and around 3–4 % for the matured
NCA.
4 Discussion
This paper illustrates the variability of the adsorption
process for bisphosphonates on apatites but common
Fig. 5 Adsorption isotherms (solid symbols) and reversibility data
(open symbols) of risedronate (pH 7.4) by HA from dilute aqueous
solutions (0–3.8 mM) at a 37 C and b 25 C; the dashed lines
indicate that no risedronate desorbs upon dilution
Fig. 6 Effect of added phosphate in solution of adsorption (mmol/L)
on the release of risedronate (wt%) from HA at 25 C and pH 7.4
Fig. 7 Kinetics of release of tiludronate (%) from several NCA with
a Ca/(P?C) = 1.38 ± 0.03: A non-maturated and non-carbonated
(Filled square); B maturated for one month and carbonated (Open
circle). The amount of initial concentration of tiludronate on each
NCA sample corresponds to the adsorption plateau of the Langmuir
isotherm, i.e. Qads (A) = 2.47 mM and Qads (B) = 1.99 mM
features have been observed. The adsorption of BPs mol-
ecules on apatites is well described by a Langmuir iso-
therm, as previously observed for bioactive molecules,
such as drugs and proteins, strongly interacting with apat-
itic surface [24–26]. However, a major characteristic of this
adsorption process is the absence of reversibility, which is
in contrast with the Langmuir theory of adsorption. As
often noticed for bioactive molecules on apatitic surfaces
[12, 27], no desorption was observed by simple dilution of
the solution or even upon washing of the samples, except
for faint release effects possibly due to the dissolution of
the apatite. However, the process was shown to be reversed
by phosphate addition. This phenomenon is commonly
observed in chromatography on apatite columns [28].
As for the interaction of organic molecules on calcium
phosphate surfaces, an interesting aspect of the adsorption
of bisphosphonate is that the parameters of adsorption can
vary depending on the physicochemical conditions of the
adsorption reaction. The results show that a decrease in pH,
an increase in temperature or a decrease in the amount of
phosphate in the solution induced an increase in the max-
imum amount adsorbed. The influence of temperature, at
pH 7.4 for example, indicates a higher adsorption limit at
physiological temperatures compared with room tempera-
ture. Indeed, the sharp rise of the adsorption curve for low
concentrations at 37 C is indicative of a greater affinity
between risedronate and the apatite surface. The increase in
the maximum amount of risedronate adsorbed with rising
temperatures seems to indicate an increase in the amount of
adsorption sites. A similar evolution of the adsorption
parameters with temperature was noticed for the interaction
of cisplatin, an anti-cancer drug [29], and pyrophosphate
[30] with HA. Yin et al. [31] also showed that increasing
the temperature resulted in an increase in the loading
capacity of bovine serum albumin by HA. Similar ten-
dencies have been reported for the effect of pH and other
parameters on the adsorption of anionic species (proteins,
citrates and amino acids) [25–27, 32]. These observations
have received different interpretations including surface
charge and/or surface energy variations, molecular con-
formation changes and speciation in the solution. In addi-
tion, the structure of the bisphosphonate molecule
influences the adsorption parameters calculated from
Langmuir isotherms, as observed for risedronate and ti-
ludronate (Fig. 2). Nancollas et al. [3] explained the
modification of HA crystal surfaces after adsorption of
several BPs by differences in solid/liquid interfacial prop-
erties. The molecular charges related to the protonation of
the BPs side-chain moieties may influence their mecha-
nisms for binding.
However, regardless of the evolution of mineral species
concentration in the adsorption solution, it seems that the
binding properties cannot be explained based only on the
physical characteristics of the interfacial properties. The
follow-up of the concentration of the mineral content of the
solution (Fig. 4) indicates that the adsorption of BP mol-
ecules is associated with a chemical phenomenon: the
release of phosphate ions, as previously published for
risedronate on HA [21] and tiludronate on several NCAs
[13], and by other authors concerning zoledronate adsorp-
tion on calcium phosphates [10]. This observation suggests
that BPs molecules substituted for phosphate ions on the
mineral surface and the adsorption of BPs can be well
described by an ion-exchange process onto the apatitic
support. The amount of phosphate ions displaced by one
molecule of bisphosphonate can then be evaluated for all
points of the isotherm, and a ratio of phosphate ions dis-
placed per BP molecule adsorbed can be calculated.
Although this ratio seems very close to 1 for risedronate
adsorption, whatever the apatitic calcium phosphate sup-
port considered (HA or NCA) [12], the ratio for tiludronate
is not equal to one or two and appears different as a
function of the nature of the NCA [13]. Thus, the adsorp-
tion reaction can be better represented as an ion-exchange
equilibrium at the surface of the apatite:
a Phosphate apatite þ BP solution
$ BP apatite þ a Phosphate solution ð3Þ
where ‘‘Phosphate’’ corresponds to phosphate species
(PO4
3- and/or HPO4
2-). This representation is consistent
with the observation of a Langmuir isotherm involving the
concentration of phosphate in solution as developed in
different reports [12, 13].
The description of the adsorption as an ion-exchange
reaction explains the apparent irreversibility of the
adsorption observed upon dilution. Because dilution with a
solution in equilibrium with the apatite support and without
BPs involves a reduction of both concentrations (concen-
tration of BPs at equilibrium and phosphate concentration
in solution) in equal proportion, the conditions of the
equilibrium are approximately unchanged. The effect of
phosphate addition on the displacement of adsorbed spe-
cies is generally assigned to a competition for the occu-
pancy of active adsorption sites on the mineral surface, in
agreement with the ion exchange reaction proposed.
Moreover, it has been found that the adsorption parameters
N and K varied with the maturation time of the apatitic
supports, related possibly to changes in chemical compo-
sition. In addition higher amounts of BPs adsorbed at sat-
uration were obtained on NCA compared to well-
crystallized HA, as observed in previous studies [13, 33].
Similar data were obtained for BSA adsorption [26] and
phosphoserine [25] indicating an increase of the affinity
constant and a decrease of the maximum amount adsorbed
at saturation with the maturation time. These results can be
explained by the presence of the hydrated layer rich in
labile species on the surface of NCA being able to
exchange, and the influence of maturation times on the
development of the surface hydrated layer and its compo-
sition. These data illustrate the variability of adsorption on
apatite substrates and the need to define and characterize
precisely the type of apatite used and its surface.
It is important to note that other phenomena could
explain the release of mineral species in solution, such as
the apatite dissolution and the formation of BP-calcium salt
[10, 34]. The adsorption of BPs weakly influences the
amount of calcium released in solution and most calcium
ions remain attached to the solid phase, thus the formation
of insoluble risedronate calcium salts must be considered as
a competitive reaction to the adsorption. The reaction on the
apatitic surface could then be written as a dissolution-
reprecipitation phenomenon and BP-calcium salt formation,
as proposed in a previous paper for Ca2BP formation [13]:
CaX PO4ð Þsolidþ X/2ð Þ BP4solution
! X/2Ca2BPsolid þ PO4ð Þ2Xsolution ð4Þ
where X represents the Ca/P ratio of the apatite support and
(PO4) the phosphate species (PO4
3- and/or HPO4
2-). In
this case, the amount of phosphates released per BP mol-
ecule in solution would be equal to 2/X, and 1/X for the
formation of the CaBP salt. Figure 4 presents the results of
phosphate concentration in solution versus the amount of
tiludronate from soluble NCA with 1 month of maturation
time and no carbonate content (Ca/P = 1.61 ± 0.02). The
slope of the straight line appears equal to 2.35 ± 0.16,
which would exclude the formation of a BP-calcium salt.
Furthermore, no other crystalline calcium phase was
detected by XRD and SEM (data not shown) and in addi-
tion the dissolution-reprecipitation process would not lead
to a Langmuir-type adsorption equilibrium in contrast to
the ion-exchange process [12].
The release kinetics of bisphosphonate molecules from
apatitic samples has been also investigated. Generally,
drugs and other biomolecules, such as growth factors, are
incorporated into apatitic calcium phosphates by impreg-
nation and drying, thus the binding properties are often
unknown and the release rate uncontrolled [35, 36]. In
contrast, adsorption on apatitic surfaces controls the
amount of such molecules and the dose released. As
observed in the current paper, bisphosphonate molecules
are slowly released from the apatitic support, because most
of the adsorbed molecules are irreversibly bound and not
spontaneously released by dilution or simple washing as
explained above [12]. They can only be displaced by a
back-exchange process with mineral ions and/or soluble
proteins from the solution, or dissolution of the support
stimulated by external chemical factors such as pH. This
characteristic has been observed for growth factors [35, 37]
and drugs [29, 38–40]. Moreover, similar to their adsorp-
tion, the release of bisphosphonates is not only strongly
affected by the chemical properties of the molecule, but
also by the chemical and structural characteristics of the
apatitic substrates. As seen in Fig. 7, maturation stage and
chemical composition of the apatitic supports affect the
development and chemical composition of the surface
hydrated layer, and thus the adsorption parameters and BPs
release. Such properties have been used by several authors
to control the release rate of proteins and drugs [14, 29,
37]. This behaviour could be useful to conceive ‘‘smart
delivery systems’’ of bisphosphonates from apatitic bio-
materials in vivo.
5 Conclusion
This work clarifies the interaction of two bisphosphonates,
risedronate and tiludronate, with several apatitic supports, a
well-crystallised hydroxyapatite (HA) and nanocrystalline
apatites (NCAs). Whatever the nature of the BP and the
structure and composition of the apatite, the adsorption of
such anti-resorptive agents can be well described as an ion
exchange-reaction between phosphates species on the ap-
atitic surface and BP molecules in solution. This descrip-
tion explains the apparent irreversibility of the adsorption
observed upon dilution. However the parameters of
adsorption can vary depending on the physicochemical
conditions of the adsorption reaction. The results show that
a decrease in pH, an increase in temperature or a decrease
in the amount of phosphate in the solution induces an
increase in the maximum amount adsorbed. Moreover, the
structure and composition of the apatitic surface also
influence the adsorption properties as an increase of mat-
uration time and changes in the chemical composition of
the apatitic supports influence the adsorption parameters,
related possibly to changes in development of the surface
hydrated layer and its chemical composition. These data
illustrate the variability of adsorption on apatite substrates
and the need to define and characterize precisely the type
of apatite used and its surface.
Finally, BPs molecules are slowly released from apatitic
supports, because most of the adsorbed molecules are
irreversibly bound and not spontaneously released by
dilution or simple washing. Moreover, similar to their
adsorption, the release of bisphosphonates is strongly
affected not only by the chemical properties of the mole-
cule, but also by the chemical and structural characteristics
of the apatitics substrates. Such properties can be used to
control the release rate of BP. This behaviour could be
useful to conceive ‘‘smart delivery systems’’ of bisphos-
phonates from apatitic biomaterials in vivo.
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